DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy
Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
This study is A Randomized, Double-blind, Placebo-controlled, Phase II Optimal Dose-finding
Study to Determine the Safety and Efficacy of DWP450 in Subjects with Benign Masseteric
Hypertrophy
Phase:
Phase 2
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A